The National Institute of Allergy and Infectious Diseases (NIAID) is seeking information from diagnostics product developers interested in supporting the advanced development of integrated clinical multiplex diagnostic technologies to detect emerging and re-emerging infectious diseases.
Targets include NIAID Priority Pathogens and other common medically-important pathogens directly from a blood sample, without a blood culture step. The primary focus of the RFI is to gather information about the current product development status of the integrated instrument and potential multiplex diagnostic test.
Areas of greatest interest include multiplexed diagnostics designed for use in a primary healthcare setting; composed of a single operating unit capable of accepting a clinical sample, or a cartridge-based operating unit; and having automated sample prep and reporting capabilities.
NIAID invites organizations to submit a white paper describing their research efforts towards developing an integrated clinical sample-to-answer multiplex diagnostic product to detect Bacillus anthracis, Yersinia pestis, Francisella tularensis and a minimum of two commonly diagnosed prevalent pathogens with similar early symptoms as the three required biothreat pathogens (fever, malaise, flu-like symptoms, etc.).
Further details are available under Solicitation Number: NIH-AI-2014009. The response deadline if February 24, 2014.
